Table 3.
In Vitro CD8 T Cell Response against Telomerase Peptides in Cancer Patients
| HLA Allele | hTRT peptide | Tumor type | Killing of tumor cells | Tumor infiltrating lymphocytes | Cancer Patient in vitroPBMC immunization R/T | Ref. | |
| Autologous primary tumor cells | Established tumor cell lines | ||||||
| A2 | p540 | Prostate | ND | T2*, LnCap | ND | 6/9 (66%) | [30] |
| Melanoma | ND | T2* | ND | 1/4 (25%) | (unpublished data) | ||
| Hematological malignancies and advanced prostate | NHL | ND | ND | 5/6 (83%) | [73] | ||
| Prostate, Breast, Lung, Gastric, NHL, Liver | Prostate cancer cells | ND | ND | 21/23 (91%) | [67] | ||
| Breast | ND | ND | ND | 11/14 (79%) | [69] | ||
| Colorectal | Colorectal cancer cells | ND | ND | 5/37 (13%) | [68] | ||
| pY572 | Prostate | ND | T2* | ND | 5/8 (62%) | (unpublished data) | |
| p865 | Colorectal | Colorectal cancer cells | ND | ND | 4/37 (11%) | [68] | |
| Breast | ND | ND | ND | 6/14 (43%) | [69] | ||
| Prostate | ND | T2* | ND | 3/6 (50%) | (unpublished data) | ||
| Melanoma | 2/3 (67%) | ||||||
| B7 | p1123 | Prostate | ND | T2-B7* | ND | 2/2 (100%) | [70] |
| A3 | p973 | Breast | U266, SK-MES-1, SK-MEL-2, NHL | T2-A3*, | ND | 4/7 (57%) | [69] |
| A24 | p1008 | Liver | ND | HepG2, HuH6 and HuH7 (Hepatoma) | ND | 6/72 (8%) | [76] |
| p845 | 6/72 (8%) | ||||||
| p167 | 9/72(13%) | ||||||
| p461 | + | 5/72 (7%) | |||||
| p324 | ND | 9/72 (13%) | |||||
| p637 | 9/72 (13%) | ||||||
R/T: responders/total, ND: Not done
*, denotes target cells pulsed with corresponding peptide